CDK8/CDK19 Inhibitor Compounds for Selective Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Dysregulation of CDK8 and CDK19, part of the Mediator kinase module, is implicated in various human diseases, particularly cancer, and existing treatments are inadequate.
Innovation Solution
Development of compounds according to Formula I, which act as inhibitors of CDK8 and/or CDK19, targeting the Mediator kinase module to modulate gene expression and treat diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for diseases involving CDK8/CDK19 dysregulation, then current standard care is provided, but therapeutic efficacy is inadequate
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (Formula I) that have optimized binding affinity to CDK8/CDK19. The compounds feature varying substituent groups (R1-R6) that can be modified to tune inhibitory potency and selectivity, thereby improving therapeutic efficacy while providing multiple treatment options for different disease contexts
2Reliability
If CDK8 and CDK19 are inhibited to treat cancer, then gene expression is modulated, but potential off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target the unique active site architecture of CDK8/CDK19. The molecular structure (Formula I) includes specific functional groups and spatial arrangements that enable selective binding to the mediator kinase module, distinguishing it from other kinases and reducing off-target effects while maintaining effective disease treatment
Data Source
AI summary
The present invention relates to compounds according to Formula I, and their use as CDK8 and/or CDK19 inhibitors.